Erste Group Bank Raises Earnings Estimates for AbbVie

AbbVie Inc. (NYSE:ABBV) – Analysts at Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Tuesday, March 24th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $16.16 for the year, up from their previous forecast of $16.11. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the firm earned $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.

Several other equities research analysts have also weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Barclays began coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $206.85 on Thursday. AbbVie has a 52-week low of $164.39 and a 52-week high of $244.81. The business has a fifty day moving average of $222.17 and a two-hundred day moving average of $224.62. The stock has a market cap of $365.74 billion, a PE ratio of 87.65, a PEG ratio of 0.71 and a beta of 0.34.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after acquiring an additional 44 shares during the period. Bank of Jackson Hole Trust increased its position in AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA increased its position in AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares during the period. Matthew Goff Investment Advisor LLC raised its holdings in AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after purchasing an additional 45 shares during the last quarter. Finally, Centennial Wealth Advisory LLC raised its holdings in AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a multi‑year partnership with Major League Baseball to expand its “Striking Out Cancer” program nationally — a high‑profile marketing and corporate‑responsibility move that should boost brand visibility and patient/public engagement without near‑term material costs. AbbVie Named Official Pharmaceutical Partner of Major League Baseball
• Positive Sentiment: Analysts and value investors are re‑examining ABBV after recent share weakness; one write‑up frames the pullback as a potential buying opportunity based on long‑term fundamentals and pipeline prospects, which can attract bargain hunters. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?
• Positive Sentiment: AbbVie’s psychiatry pipeline expansion (acquisition of bretisilocin) keeps the company positioned in fast‑growing neuropsychiatric markets; the deal supports longer‑term revenue diversification beyond core immunology and oncology franchises. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Neutral Sentiment: Investor attention and search interest in ABBV have spiked, which can increase short‑term volatility but doesn’t signal direction on its own. Investors Heavily Search AbbVie Inc. (ABBV)
• Neutral Sentiment: Related sector financing (e.g., Gilgamesh Pharma’s Series A) signals investor appetite for neuropsychiatric assets but is peripheral to AbbVie’s near‑term earnings. Gilgamesh Pharma Closes Oversubscribed $60 Million Series A
• Negative Sentiment: Competitive dynamics: analysts highlight that rivals (notably Eli Lilly) are seeing explosive growth from obesity medicines, whereas AbbVie’s near‑term growth remains concentrated in Skyrizi and Rinvoq—this relative growth gap could limit upside and keep valuation under pressure. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.